Organization
Allergy Therapeutics
3 clinical trials
2 abstracts
Clinical trial
A Long-term, Prospective, Open, Multi-centre, Non-interventional Study to Evaluate the Effectiveness After Treatment With TA Bäume Top (Trees) and TA Gräser Top (Grass) Following a Perennial Posology in Children and Adults, as Well as Proofing the Non-inferiority of Children Compared to AdultsStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
A Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen ExposureStatus: Completed, Estimated PCD: 2023-11-01
Clinical trial
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)Status: Recruiting, Estimated PCD: 2025-10-01
Abstract
ADALIMUMAB CLINICAL EFFICACY IS ASSOCIATED WITH RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY TITRE REDUCTION: A 6-MONTH PROSPECTIVE STUDYOrg: Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, L Sacco University Hospital, Pharmacoeconomy Centre, Chair of Pharmacology, University of Milano, European Institute of Oncology, Division of Early Drug Development,
Abstract
AUTOANTIBODIES TO CYCLIC CITRULLINATED PEPTIDE 2 (CCP2) ARE SUPERIOR TO OTHER POTENTIAL DIAGNOSTIC BIOMARKERS FOR PREDICTING DEVELOPMENT OF RHEUMATOID ARTHRITIS (RA) IN EARLY UNDIFFERENTIATED ARTHRITISOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Allergy Therapeutics, Clinical Research Centre, Cardiology Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy, NHO Osaka-Minami Medical Center,